Telix Reports Third Quarter 2022 Financial Results
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September...
Read moreLatest News
Category: News
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM
Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of...
Read more
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
Read more
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
Read more
Health Canada Approves Illuccix® for Prostate Cancer Imaging
Telix announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localizing...
Read more
Join Telix at EANM 2022 to discover how nuclear medicine is shifting perspectives in Genitourinary Oncology
Read more
The Role of Patents in Drug Development – Telix in Australian Biotechnology Journal
News,
As printed in Australasian Biotechnology Journal September 2022 | Volume 32 | Number...
Read more
First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Telix today announces the first commercial dose in New Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11...
Read more